12-13-06

Express Mail Label No. EV 326 984 870 US

Attorney Docket No. 59150-8037

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF: NAGAIKE et al.

Application No.: 10/591,787

IA Filing Date: March 3, 2005

FOR: RECOMBINANT VARICELLA-ZOSTER VIRUS

EXAMINER: To be Assigned

ART UNIT: 1642

CONF. No. 3253

<u>Information Disclosure Statement Within Three Months of</u>
<u>Application Filing or Before First Action – 37 C.F.R. § 1.97(b)</u>

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an International Application or before the mailing date of a first Office Action on the merits or before the mailing date of a first Office Action on the merits after the filing of a Request for Continued Examination under 37 CFR §1.114, whichever occurs last (37 CFR 1.97(b)(4)). The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

□ Copies of references 1-10 are enclosed.

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 C	C.F.R. § 1.704(d)
---------------------------------	-------------------

		The und	ersigne	d state	s that e	ach ite	m of ir	nformat	ion su	ıbmitte	ed here	ewith	was
cited in	ı a	commu	nication	from a	foreigr	n pater	nt office	e in a d	count	erpart	applic	ation	and
that thi	is (commun	cation	was no	t receiv	ved by	any i	ndividu	al de	signat	ed in	37 C.	F.R.
§ 1.56(c) ı	more tha	n thirty	days pi	ior to th	e filing	of this	staten	nent.	37 C.	F.R. §	1.704	l(d).

Respectfully submitted, Perkins Coie LLP

Date: DCC . 11, 2006

Jacqueline F. Mahoney Registration No. 48,390

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300

COMPLETE IF KNOWN 10/591,787 **Application Number INFORMATION DISCLOSURE** Confirmation Number 3253 O / STATEMENT BY APPLICANT Filing Date March 3, 2005 Korm PTO-1449 (Modified) First Named Inventor Nagaike et al. (Use several sheets if necessary) 1642 Group Art Unit **Examiner Name** To be Assigned of Attorney Docket No. 59150-8037

- West	BK OFF				U	.S. PATENT DOCUMENTS				
Examiner Initials*	Cit				Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines Where Relevant Passag or Relevant Figures App			
		<u></u>		<u> </u>	FOR	EIGN PATENT DOCUMENTS		<u> </u>		
Examiner Initials*	Cite No.	Fore	eign Patent or A	Application Kind ((if kn	Code	Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т	
	1. PCT WO00/50603				The Research Foundation for Microbial Diseases of Osaka University					
	2.	PCT WO02/12288 A2				Lohmann Animal Health GMBH & Co. KG	2/14/02			
			OTHER	RPRIOF	R AR	Γ-NON PATENT LITERATURE DO	CUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.								
	3.	3. Adler et al., Journal of Virology, 74(15):6964-6974 (2000).								
	4.	Borst et al., Journal of Virology, <u>73</u> (10):8320-8329 (1999).								
	5.	Davison et al., Journal General Virology, 67:1759-1816 (1986).								
	6.	Gomi et al., Journal of Virology, <u>76</u> (22):11447-11459 (2002).								
	7.	Messerle <i>et al.</i> , <i>PNAS USA</i> , <u>94</u> :14759-14763 (1997).								
	8.	Nagaike <i>et al.</i> , <i>Vaccine</i> , <u>22</u> :4069-4074 (2004).								
	9.	Schumacher et al., Journal of Virology, 74(23):11088-11098 (2000).								
	10.	Tanaka et al., Journal of Virology, 77(2):1382-1391 (2003).								

EXAMINER		DATE CONSIDERED					
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not						
	considered. Include copy of this form with next communication to application(s).						